Complement C5

Description:

Description
  • Accession: P01031
  • Swissprot: CO5_HUMAN
  • Organism: Homo sapiens
  • Gene: C5
  • Target classes: Secreted, Unclassified

Drug Relations:

eculizumab
a recombinant humanized monoclonal IgG2/4k antibody produced by murine myeloma cell culture, specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9 Bioactivity details MOA
ravulizumab
Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the terminal complement complex [C5b-9]) and preventing the generation of the terminal complement complex C5b9. ULTOMIRIS inhibits terminal complement-mediated intravascular hemolysis in patients with PNH. Bioactivity details MOA